Characteristics

Study participants (n = 38)

Age (yr)

73.2 ± 8.6

Sex (n)

17 men, 21 women

Disease duration (yr)

8.8 ± 5.9

MMSE (score)

27.3 ± 1.9

H-Y stage

2.8 ± 0.7

Forward flexion (˚)

10.7 ± 17.5

Lateral flexion (˚)

10.1 ± 12.9 (R:23)

UPDRS Part III (score)

16.9 ± 10.2

Postural stability (score) (UPDRS item 30)

1.7 ± 1.1

TUG (sec)

13.3 ± 5.8

L-Dopa (mg)

100% (n = 38)

373.7 ± 120.7

Dopamine agonist (mg)

89.5% (n = 34)

Pramipexole 1.86 ± 0.84 (n = 21)

Ropinirole 7.25 ± 2.64 (n = 11)

Rotigotine 12 ± 3.18 (n = 2)

MAO-B blocker (mg)

57.9 % (n = 22)

Amantadine (mg)

26.3% (n = 10)

COMT inhibitor (mg)

26.3% (n = 10)